1. Osteopontin is a therapeutic target that drives breast cancer recurrence.
- Author
-
Gu Y, Taifour T, Bui T, Zuo D, Pacis A, Poirier A, Attalla S, Fortier AM, Sanguin-Gendreau V, Pan TC, Papavasiliou V, Lin NU, Hughes ME, Smith K, Park M, Tremblay ML, Chodosh LA, Jeselsohn R, and Muller WJ
- Subjects
- Female, Animals, Humans, Mice, Cell Line, Tumor, Macrophages metabolism, Interleukin-4 metabolism, Gene Expression Regulation, Neoplastic, Prognosis, Osteopontin metabolism, Osteopontin genetics, Breast Neoplasms pathology, Breast Neoplasms metabolism, Breast Neoplasms genetics, Breast Neoplasms drug therapy, Neoplasm Recurrence, Local prevention & control, Neoplasm Recurrence, Local metabolism, Cell Proliferation
- Abstract
Recurrent breast cancers often develop resistance to standard-of-care therapies. Identifying targetable factors contributing to cancer recurrence remains the rate-limiting step in improving long-term outcomes. In this study, we identify tumor cell-derived osteopontin as an autocrine and paracrine driver of tumor recurrence. Osteopontin promotes tumor cell proliferation, recruits macrophages, and synergizes with IL-4 to further polarize them into a pro-tumorigenic state. Macrophage depletion and osteopontin inhibition decrease recurrent tumor growth. Furthermore, targeting osteopontin in primary tumor-bearing female mice prevents metastasis, permits T cell infiltration and activation, and improves anti-PD-1 immunotherapy response. Clinically, osteopontin expression is higher in recurrent metastatic tumors versus female patient-matched primary breast tumors. Osteopontin positively correlates with macrophage infiltration, increases with higher tumor grade, and its elevated pathway activity is associated with poor prognosis and long-term recurrence. Our findings suggest clinical implications and an alternative therapeutic strategy based on osteopontin's multiaxial role in breast cancer progression and recurrence., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF